Is there an Indian generic version of Entrectinib?

Entrectinib (Entrectinib) is a multi-target oral targeted therapy drug, mainly used to treat specific gene fusion-positive tumors, including non-small cell lung cancer (NSCLC) and some other solid tumors.

There is currently no Indian generic version of entrectinib that is officially marketed. Entrectinib has been launched in China, but due to its short time on the market, it has not yet been included in the medical insurance catalog. Since it has just been launched, it is difficult to purchase domestically and the price is very high. For specific prices, please consult the hospital pharmacy at that time. There are original drugs and generic drugs abroad. The original drugs abroad are mainly European versions of original drugs. The price is about 45,000 yuan. The price is relatively high and may be unaffordable for ordinary families. Generic drugs are mainly Lao generic drugs, with prices ranging from 4,000 to 8,000yuan, which are much cheaper than original drugs, and the ingredients of original drugs and generic drugs are basically the same.

Enrectinib is mainly used to treat patients with NSCLC carrying EGFR, ROS1 and ALK gene fusions. These gene fusions can occur in some patients with NSCLC, causing tumors to grow and spread. Entrectinib inhibits the activity of these gene fusion proteins, thereby interfering with the signaling pathways of tumor cells and achieving the purpose of inhibiting tumor growth.

In addition toNSCLC, entrectinib has also shown potential application value in the treatment of other solid tumors. For example, entrectinib can also be used to treat tumors that carry NTRK gene fusions, which are found in a variety of cancers.

The use of entrectinib is individualized and selected based on the patient's genotype and tumor characteristics. In clinical practice, doctors will use genetic testing and other methods to determine whether a patient is suitable for entrectinib and which gene fusion is present in his or her tumor.